Form 4: Marimed COO Timothy Shaw's Routine Stock Transactions

Marimed Inc. COO Timothy Shaw reported the conversion of Restricted Stock Units into common stock and subsequent tax-related share disposition, impacting his direct beneficial ownership.

Summary

• Timothy Shaw, Chief Operating Officer of Marimed Inc. (MRMD), reported stock transactions on October 2, 2025.
• 9,981 Restricted Stock Units (RSUs) converted into common stock on a one-for-one basis.
• 2,930 shares of common stock were withheld by the Issuer to satisfy tax withholding obligations in connection with the RSU vesting, at a price of $0.161 per share.
• Following these transactions, Shaw directly beneficially owns 9,055,412 shares of common stock.
• He also indirectly owns 2,000,000 shares through the Shaw Family Trust, for which he disclaims beneficial ownership.
• The remaining 29,945 RSUs are scheduled to vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding, which is a standard part of executive compensation and does not indicate a significant positive or negative shift in company fundamentals or outlook.

Positives

• The vesting of 9,981 Restricted Stock Units (RSUs) demonstrates ongoing equity compensation and retention of a key executive.

Negatives

• 2,930 shares of common stock were disposed of to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The remaining 29,945 Restricted Stock Units (RSUs) held by Timothy Shaw are scheduled to vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027, indicating future equity compensation and a continued alignment of executive incentives with shareholder interests.

Management Comments

• Timothy Shaw disclaims beneficial ownership of the 2,000,000 shares held by the Shaw Family Trust, stating that his spouse is the trustee and the shares are for the benefit of his children, and the trust is irrevocable.

Industry Context

This filing represents a routine insider transaction, common for executives receiving equity compensation. It reflects the vesting of previously granted Restricted Stock Units (RSUs) and the standard practice of withholding shares to cover tax obligations upon vesting. Such transactions are typical across industries for executive compensation plans and do not typically signal a change in company strategy or performance.

Comparison to Industry Standards

• NA

Related Party Transactions

• Indirect beneficial ownership of 2,000,000 shares through the Shaw Family Trust, where the reporting person's spouse is the trustee and the shares benefit their children. The reporting person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock represents a minor, pre-planned increase in outstanding shares, which is a routine aspect of equity compensation plans.
• Management: Timothy Shaw's equity stake is adjusted due to the vesting of RSUs and the subsequent disposition of shares for tax obligations, reflecting the execution of his compensation agreement.

Next Steps

• Remaining 29,945 RSUs will vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to executive compensation (RSU vesting and tax withholding). It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Marimed, MRMD, Timothy Shaw, COO, Form 4, RSU, stock transaction, insider trading, beneficial ownership, equity compensation